Amgen Inc. has won a patent infringement verdict worth $10 billion.

No damages were in play in Immunex v. Sandoz, but Amgen’s market cap popped $10 billion Monday on news that it successfully defended two patents on its rheumatoid arthritis biopharmaceutical Enbrel.